HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 74.5%

Neg 0% Neu 0% Pos 74.5%

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $12 to $25.